Literature DB >> 29853466

Evolution of Age and Female Representation in the Most-Cited Randomized Controlled Trials of Cardiology of the Last 20 Years.

Quoc Dinh Nguyen1, Eric Peters2, Andreanne Wassef3, Philippe Desmarais4, Delphine Rémillard-Labrosse5, Maxime Tremblay-Gravel6.   

Abstract

BACKGROUND: Older adults and women have historically been underrepresented in randomized controlled trials of cardiology. Recent temporal evolution and factors influencing representation are incompletely investigated. We aimed to contrast age and female representation in the most influential randomized controlled trials in cardiology of the last 20 years to population prevalence and to assess the study factors affecting representation. METHODS AND
RESULTS: Using Web of Science, we selected the 25 most-cited cardiology articles each year between 1996 and 2015, and extracted mean age, percentage of women, funding source, sample size, disease condition, intervention type, and exclusion criteria. The outcomes were the evolution of the mean age and the percentage of women over time. Protocol design elements and year of publication were assessed as predictors of outcomes in multivariable regressions. A total of 500 studies were analyzed, where the mean age was 62.6±7.4 years and the median percentage of women was 28.6% (22.2-40.5). Compared with population prevalence derived from National Health and Nutrition Examination Survey 2015-2016, gaps in representation were apparent and more pronounced for coronary artery disease (-5.0 years; -27.2% women) and heart failure (-6.0 years; -25.4% women). The mean age (0.15 year per year; 95% confidence interval, 0.04-0.26) and percentage of women (+0.29% per year; 95% confidence interval, 0.07-0.50), slightly but significantly increased over time. Private funding, small sample size, and exclusions pertaining to maximal age, atrial fibrillation, and diabetes mellitus were associated with a decreased mean age in multivariable linear regressions. Age and life expectancy exclusions were associated with lower female percentage.
CONCLUSIONS: Although age and female representation increased over time, the modest trends are unlikely to resolve the persistently wide gaps with actual populational prevalence, especially for coronary artery disease and HF. Representation is modulated by the cardiovascular condition studied and some modifiable protocol elements.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  acute coronary syndrome; aging; coronary artery disease; life expectancy; women

Mesh:

Year:  2018        PMID: 29853466     DOI: 10.1161/CIRCOUTCOMES.118.004713

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  11 in total

1.  Differences in Management of Coronary Artery Disease in Patients With Medicare Advantage vs Traditional Fee-for-Service Medicare Among Cardiology Practices.

Authors:  Jose F Figueroa; Daniel M Blumenthal; Yevgeniy Feyman; Austin B Frakt; Alexander Turchin; Gheorghe Doros; Qi Gao; Yang Song; Karen E Joynt Maddox
Journal:  JAMA Cardiol       Date:  2019-03-01       Impact factor: 14.676

2.  Sex Differences in the Impact of Aortic Valve Calcium Score on Mortality After Transcatheter Aortic Valve Replacement.

Authors:  Parth P Patel; Abdallah El Sabbagh; Patrick W Johnson; Rayan Suliman; Najiyah Salwa; Andrea Carolina Morales-Lara; Peter Pollak; Mohamad Yamani; Pragnesh Parikh; Sushilkumar K Sonavane; Carolyn Landolfo; Mohamad Adnan Alkhouli; Mackram F Eleid; Mayra Guerrero; F David Fortuin; John Sweeney; Peter A Noseworthy; Rickey E Carter; Demilade Adedinsewo
Journal:  Circ Cardiovasc Imaging       Date:  2022-08-03       Impact factor: 8.589

Review 3.  An Update on Medication Use in Older Adults: a Narrative Review.

Authors:  Heather E Barry; Carmel M Hughes
Journal:  Curr Epidemiol Rep       Date:  2021-07-20

4.  Systematic Incorporation of Sex-Specific Information Into Clinical Practice Guidelines for the Management of ST -Segment-Elevation Myocardial Infarction: Feasibility and Outcomes.

Authors:  Colleen M Norris; Cara Tannenbaum; Louise Pilote; Graham Wong; Warren J Cantor; Micheal S McMurtry
Journal:  J Am Heart Assoc       Date:  2019-04-02       Impact factor: 5.501

Review 5.  Cardiovascular Disease and the Female Disadvantage.

Authors:  Mark Woodward
Journal:  Int J Environ Res Public Health       Date:  2019-04-01       Impact factor: 3.390

Review 6.  Sex, Race, and Age Differences in Cardiovascular Outcomes in Implantable Cardioverter-Defibrillator Randomized Controlled Trials: A Systematic Review and Meta-analysis.

Authors:  Mohammad K Syed; Hassan I Sheikh; Bradley McKay; Nicholas Tseng; Maureen Pakosh; Jessica E Caterini; Abhinav Sharma; Tracey J F Colella; Kaja M Konieczny; Kim A Connelly; Michelle M Graham; Michael McDonald; Laura Banks; Varinder Kaur Randhawa
Journal:  CJC Open       Date:  2021-09-24

Review 7.  Sex, Race, and Age Differences of Cardiovascular Outcomes in Cardiac Resynchronization Therapy RCTs: A Systematic Review and Meta-analysis.

Authors:  Bradley McKay; Nicholas W H Tseng; Hassan I Sheikh; Mohammad K Syed; Maureen Pakosh; Jessica E Caterini; Abhinav Sharma; Tracey J F Colella; Kaja M Konieczny; Kim A Connelly; Michelle M Graham; Michael McDonald; Laura Banks; Varinder Kaur Randhawa
Journal:  CJC Open       Date:  2021-09-15

8.  Sex and gender reporting in global health: new editorial policies.

Authors:  Sanne A E Peters; Robyn Norton
Journal:  BMJ Glob Health       Date:  2018-07-26

Review 9.  Sex differences on peak oxygen uptake in heart failure.

Authors:  Patricia Palau; Eloy Domínguez; Julio Núñez
Journal:  ESC Heart Fail       Date:  2019-07-19

10.  Impact of sex differences in co-morbidities and medication adherence on outcome in 25 776 heart failure patients.

Authors:  Muhammed T Gürgöze; Onno P van der Galiën; Marlou A M Limpens; Stefan Roest; René C Hoekstra; Arne S IJpma; Jasper J Brugts; Olivier C Manintveld; Eric Boersma
Journal:  ESC Heart Fail       Date:  2020-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.